KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma

Joanne Van Der Velden, Grace Sum, Donna Barker, Emmanuel Koumoundouros, Garry Barcham, Heike Wulff, Neil Castle, Peter Bradding, Kenneth Snibson

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background:The Ca2+-activated K+ channel KCa3.1 is expressed in several structural and inflammatory airway cell types and is proposed to play an important role in the pathophysiology of asthma. The aim of the current study was to determine whether inhibition of KCa3.1 modifies experimental asthma in sheep.Methodology and Principal Findings:Atopic sheep were administered either 30 mg/kg Senicapoc (ICA-17073), a selective inhibitor of the KCa3.1-channel, or vehicle alone (0.5% methylcellulose) twice daily (orally). Both groups received fortnightly aerosol challenges with house dust mite allergen for fourteen weeks. A separate sheep group received no allergen challenges or drug treatment. In the vehicle-control group, twelve weeks of allergen challenges resulted in a 60±19% increase in resting airway resistance, and this was completely attenuated by treatment with Senicapoc (0.25±12%; n = 10, P = 0.0147). The vehicle-control group had a peak-early phase increase in lung resistance of 82±21%, and this was reduced by 58% with Senicapoc treatment (24±14%; n = 10, P = 0.0288). Senicapoc-treated sheep also demonstrated reduced airway hyperresponsiveness, requiring a significantly higher dose of carbachol to increase resistance by 100% compared to allergen-challenged vehicle-control sheep (20±5 vs. 52±18 breath-units of carbachol; n = 10, P = 0.0340). Senicapoc also significantly reduced eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and reduced vascular remodelling.Conclusions:These findings suggest that KCa3.1-activity contributes to allergen-induced airway responses, inflammation and vascular remodelling in a sheep model of asthma, and that inhibition of KCa3.1 may be an effective strategy for blocking allergen-induced airway inflammation and hyperresponsiveness in humans.

Original languageEnglish (US)
Article numbere66886
JournalPLoS One
Volume8
Issue number6
DOIs
StatePublished - Jun 24 2013

Fingerprint

asthma
pathophysiology
allergens
Allergens
Sheep
Asthma
sheep
carbachol
Carbachol
blood vessels
Dermatophagoides Antigens
Inflammation
Airway Remodeling
Drug therapy
inflammation
Calcium-Activated Potassium Channels
Control Groups
Airway Resistance
Methylcellulose
dust mites

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Van Der Velden, J., Sum, G., Barker, D., Koumoundouros, E., Barcham, G., Wulff, H., ... Snibson, K. (2013). KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma. PLoS One, 8(6), [e66886]. https://doi.org/10.1371/journal.pone.0066886

KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma. / Van Der Velden, Joanne; Sum, Grace; Barker, Donna; Koumoundouros, Emmanuel; Barcham, Garry; Wulff, Heike; Castle, Neil; Bradding, Peter; Snibson, Kenneth.

In: PLoS One, Vol. 8, No. 6, e66886, 24.06.2013.

Research output: Contribution to journalArticle

Van Der Velden, J, Sum, G, Barker, D, Koumoundouros, E, Barcham, G, Wulff, H, Castle, N, Bradding, P & Snibson, K 2013, 'KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma', PLoS One, vol. 8, no. 6, e66886. https://doi.org/10.1371/journal.pone.0066886
Van Der Velden, Joanne ; Sum, Grace ; Barker, Donna ; Koumoundouros, Emmanuel ; Barcham, Garry ; Wulff, Heike ; Castle, Neil ; Bradding, Peter ; Snibson, Kenneth. / KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{cf889f8c0d994fd38b0508a06f1b492d,
title = "KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma",
abstract = "Background:The Ca2+-activated K+ channel KCa3.1 is expressed in several structural and inflammatory airway cell types and is proposed to play an important role in the pathophysiology of asthma. The aim of the current study was to determine whether inhibition of KCa3.1 modifies experimental asthma in sheep.Methodology and Principal Findings:Atopic sheep were administered either 30 mg/kg Senicapoc (ICA-17073), a selective inhibitor of the KCa3.1-channel, or vehicle alone (0.5{\%} methylcellulose) twice daily (orally). Both groups received fortnightly aerosol challenges with house dust mite allergen for fourteen weeks. A separate sheep group received no allergen challenges or drug treatment. In the vehicle-control group, twelve weeks of allergen challenges resulted in a 60±19{\%} increase in resting airway resistance, and this was completely attenuated by treatment with Senicapoc (0.25±12{\%}; n = 10, P = 0.0147). The vehicle-control group had a peak-early phase increase in lung resistance of 82±21{\%}, and this was reduced by 58{\%} with Senicapoc treatment (24±14{\%}; n = 10, P = 0.0288). Senicapoc-treated sheep also demonstrated reduced airway hyperresponsiveness, requiring a significantly higher dose of carbachol to increase resistance by 100{\%} compared to allergen-challenged vehicle-control sheep (20±5 vs. 52±18 breath-units of carbachol; n = 10, P = 0.0340). Senicapoc also significantly reduced eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and reduced vascular remodelling.Conclusions:These findings suggest that KCa3.1-activity contributes to allergen-induced airway responses, inflammation and vascular remodelling in a sheep model of asthma, and that inhibition of KCa3.1 may be an effective strategy for blocking allergen-induced airway inflammation and hyperresponsiveness in humans.",
author = "{Van Der Velden}, Joanne and Grace Sum and Donna Barker and Emmanuel Koumoundouros and Garry Barcham and Heike Wulff and Neil Castle and Peter Bradding and Kenneth Snibson",
year = "2013",
month = "6",
day = "24",
doi = "10.1371/journal.pone.0066886",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma

AU - Van Der Velden, Joanne

AU - Sum, Grace

AU - Barker, Donna

AU - Koumoundouros, Emmanuel

AU - Barcham, Garry

AU - Wulff, Heike

AU - Castle, Neil

AU - Bradding, Peter

AU - Snibson, Kenneth

PY - 2013/6/24

Y1 - 2013/6/24

N2 - Background:The Ca2+-activated K+ channel KCa3.1 is expressed in several structural and inflammatory airway cell types and is proposed to play an important role in the pathophysiology of asthma. The aim of the current study was to determine whether inhibition of KCa3.1 modifies experimental asthma in sheep.Methodology and Principal Findings:Atopic sheep were administered either 30 mg/kg Senicapoc (ICA-17073), a selective inhibitor of the KCa3.1-channel, or vehicle alone (0.5% methylcellulose) twice daily (orally). Both groups received fortnightly aerosol challenges with house dust mite allergen for fourteen weeks. A separate sheep group received no allergen challenges or drug treatment. In the vehicle-control group, twelve weeks of allergen challenges resulted in a 60±19% increase in resting airway resistance, and this was completely attenuated by treatment with Senicapoc (0.25±12%; n = 10, P = 0.0147). The vehicle-control group had a peak-early phase increase in lung resistance of 82±21%, and this was reduced by 58% with Senicapoc treatment (24±14%; n = 10, P = 0.0288). Senicapoc-treated sheep also demonstrated reduced airway hyperresponsiveness, requiring a significantly higher dose of carbachol to increase resistance by 100% compared to allergen-challenged vehicle-control sheep (20±5 vs. 52±18 breath-units of carbachol; n = 10, P = 0.0340). Senicapoc also significantly reduced eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and reduced vascular remodelling.Conclusions:These findings suggest that KCa3.1-activity contributes to allergen-induced airway responses, inflammation and vascular remodelling in a sheep model of asthma, and that inhibition of KCa3.1 may be an effective strategy for blocking allergen-induced airway inflammation and hyperresponsiveness in humans.

AB - Background:The Ca2+-activated K+ channel KCa3.1 is expressed in several structural and inflammatory airway cell types and is proposed to play an important role in the pathophysiology of asthma. The aim of the current study was to determine whether inhibition of KCa3.1 modifies experimental asthma in sheep.Methodology and Principal Findings:Atopic sheep were administered either 30 mg/kg Senicapoc (ICA-17073), a selective inhibitor of the KCa3.1-channel, or vehicle alone (0.5% methylcellulose) twice daily (orally). Both groups received fortnightly aerosol challenges with house dust mite allergen for fourteen weeks. A separate sheep group received no allergen challenges or drug treatment. In the vehicle-control group, twelve weeks of allergen challenges resulted in a 60±19% increase in resting airway resistance, and this was completely attenuated by treatment with Senicapoc (0.25±12%; n = 10, P = 0.0147). The vehicle-control group had a peak-early phase increase in lung resistance of 82±21%, and this was reduced by 58% with Senicapoc treatment (24±14%; n = 10, P = 0.0288). Senicapoc-treated sheep also demonstrated reduced airway hyperresponsiveness, requiring a significantly higher dose of carbachol to increase resistance by 100% compared to allergen-challenged vehicle-control sheep (20±5 vs. 52±18 breath-units of carbachol; n = 10, P = 0.0340). Senicapoc also significantly reduced eosinophil numbers in bronchoalveolar lavage taken 48 hours post-allergen challenge, and reduced vascular remodelling.Conclusions:These findings suggest that KCa3.1-activity contributes to allergen-induced airway responses, inflammation and vascular remodelling in a sheep model of asthma, and that inhibition of KCa3.1 may be an effective strategy for blocking allergen-induced airway inflammation and hyperresponsiveness in humans.

UR - http://www.scopus.com/inward/record.url?scp=84879491623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879491623&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0066886

DO - 10.1371/journal.pone.0066886

M3 - Article

C2 - 23826167

AN - SCOPUS:84879491623

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e66886

ER -